PCP
LGND icon

Perimeter Capital Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Perimeter Capital Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-8,709
Closed -$255K – 17
2014
Q3 		$255K Sell
8,709
-32,632
-79% -$1.08M 0.43% 58
2014
Q2 		$1.61M Buy
41,341
+4,055
+11% +$165K 0.82% 28
2014
Q1 		$1.56M Sell
37,286
-6,332
-15% -$264K 0.78% 39
2013
Q4 		$1.43M Buy
43,618
+424
+1% +$13.8K 0.7% 54
2013
Q3 		$1.17M Buy
+43,194
New +$1.22M 0.22% 153

Other funds holding LGND

RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perimeter Capital Partners's LGND Position: Q4 2014 in Review

Perimeter Capital Partners sold out of Ligand Pharmaceuticals (LGND) in Q4 2014, closing a stake of 8,709 shares — an estimated $255K sold.

Perimeter Capital Partners first reported a position in LGND in Q3 2013 and held it in 5 quarters. The position peaked at $1.61M in Q2 2014. 180 funds tracked by Wall St. Rank hold LGND as of Q4 2014.

  • Perimeter Capital Partners reported no remaining Ligand Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Perimeter Capital Partners sold 8,709 Ligand Pharmaceuticals shares in Q4 2014, an estimated $255K.
  • Perimeter Capital Partners first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 5 quarters.
  • Perimeter Capital Partners's Ligand Pharmaceuticals position peaked at $1.61M in Q2 2014.
  • 180 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2014.

Based on Perimeter Capital Partners's 13F filing for Q4 2014.